Although previous studies reported antitumor effects of ZAK knockdown in GBM and medulloblastoma [30, 31], we sought to verify the expression and molecular function of MLK1 and MLK2 specifically in glioma. The gene discussed is MAP3K9; the disease is central nervous system cancer.